Rocket Pharmaceuticals, Inc. Finance Lease, Liability, to be Paid, after Year Five
Rocket Pharmaceuticals, Inc. (RCKT) had Finance Lease, Liability, to be Paid, after Year Five of $36.76 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-02-26
- 2025-12-31: Finance Lease, Liability, to be Paid, after Year Five $36.76M.
- 2024-12-31: Finance Lease, Liability, to be Paid, after Year Five $38.91M.
- 2023-12-31: Finance Lease, Liability, to be Paid, after Year Five $41.00M.
- 2022-12-31: Finance Lease, Liability, to be Paid, after Year Five $43.03M.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $36.76M 10-K · filed 2026-02-26 |
| 2024-12-31 | $38.91M 10-K · filed 2025-02-27 |
| 2023-12-31 | $41.00M 10-K · filed 2024-02-27 |
| 2022-12-31 | $43.03M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |